A Commercially-Viable MEMS-based Ultrasonic Volume Flow Sensor

一种商业化的基于 MEMS 的超声波体积流量传感器

• 批准号: 8058361
• 负责人: David Frederick Lemmerhirt
• 金额: $ 18.7万
• 依托单位: SONETICS ULTRASOUND, INC.
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-15 至 2012-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8058361
• 关键词: Accounting; Address; Blood Vessels; Blood Volume; Blood flow; Caring; Clinical; Communication; Computer software; Dependence; Development; Devices; Dialysis patients; Dialysis procedure; Electronics; Elements; End stage renal failure; Failure; Future; Goals; Health; Health Care Costs; Healthcare Industry; Healthcare Systems; Hemodialysis; ImProv; Legal patent; Level of Evidence; Marketing; Measurement; Michigan; Minor; Monitor; Motion; Outcome; Output; Partner in relationship; Patients; Peripheral; Peripheral Vascular Diseases; Peripheral arterial disease; Phase; Physiologic pulse; Positioning Attribute; Process; Public Health; Reading; Research; Research Personnel; Scanning; Signal Transduction; Silicon; Societies; Sum; System; Techniques; Technology; Testing; Time; Transducers; Ultrasonic Transducer; Ultrasonics; Ultrasonography; Universities; Variant; Width; Wireless Technology; Work; Writing; base; cost; data exchange; design; improved; innovation; meetings; monitoring device; novel; operation; patient population; programs; research study; sensor

DESCRIPTION (provided by applicant): The goal of the proposed program is to address several technical feasibility questions (in Phase I), and then demonstrate (in a subsequent Phase II) a compact affordable device for operator-independent monitoring of blood volume flow, particularly in the setting of hemodialysis treatment for those with end-stage renal disease (ESRD). Phase I specific aims will investigate the feasibility of using Sonetics' CMUT-in-CMOS ultrasound transducer technology to build an ultrasound array with a steerable transmit beam and a digitally-controlled receive aperture. System-level hardware and software will be developed to control the array operation and to capture Doppler signals indicative of volume flow. Phase I experiments with this array will evaluate its ability to reduce operator-dependence and to achieve good flow-sensing ability while maintaining a compact, low profile that will not interfere with dialysis treatment. Feasibility will also be determined for using this array to obtain vessel-size and insonification angle information, such that the array could be employed to meet the broader need for accurate blood volume flow measurements outside of the ESRD setting. In Phase II, the array, together with electronics for automated control, signal acquisition, and possibly wireless communication will be integrated into an ultra-compact flow-sensing patch. The clinical market stands to benefit greatly from this innovation, given that over 330,000 patients suffer from ESRD in the US alone. These patients require dialysis treatment three times per week, which costs the U.S. healthcare system over $10 billion annually. Maintaining healthy vascular access for dialysis treatment is a difficult and important problem, which accounts for over 10% the cost of dialysis care. Regular access monitoring has been shown to significantly reduce access failures, and with the frequent low-cost monitoring that would be possible with the device proposed here, failure rate would be even lower. This would have wide- ranging benefits, enabling better patient outcomes, reducing staffing needs, and reducing the skyrocketing costs in the U.S. healthcare industry. PUBLIC HEALTH RELEVANCE: Potential benefits to public health from the successful development of Sonetics' novel ultrasound-based flow monitor include: reduced health complications for dialysis patients receiving treatment for end-stage renal disease, reduced staffing needs as flow- monitoring devices become less operator dependent, and reduced health-care costs for society as a whole, as dialysis patients place a lower demand on the health-care system. Furthermore, if automated blood flow sensing becomes more widely deployed, health outcomes will improve for additional patient populations such as those with peripheral arterial disease.

描述（由申请人提供）：拟定项目的目标是解决几个技术可行性问题（I期），然后证明（在随后的II期）一种紧凑型经济型器械，用于独立于操作员的血流量监测，特别是在终末期肾病（ESRD）患者的血液透析治疗环境中。第一阶段的具体目标将研究使用Sonetics的CMUT-in-CMOS超声换能器技术构建具有可操纵发射波束和数字控制接收孔径的超声阵列的可行性。将开发系统级硬件和软件，以控制阵列操作并捕获指示体积流量的多普勒信号。使用该阵列的第一阶段实验将评估其减少操作员依赖性的能力，并在保持紧凑、低轮廓的同时实现良好的流量传感能力，不会干扰透析治疗。还将确定使用该阵列获得血管尺寸和声穿透角度信息的可行性，以便该阵列可用于满足ESRD设置之外的准确血流量测量的更广泛需求。在第二阶段，该阵列与用于自动控制、信号采集和可能的无线通信的电子设备一起将被集成到一个超紧凑的流量传感贴片中。临床市场将从这一创新中受益匪浅，因为仅在美国就有超过330，000名患者患有ESRD。这些患者每周需要进行三次透析治疗，每年花费美国医疗保健系统超过100亿美元。维持健康的血管通路进行透析治疗是一个困难而重要的问题，占透析护理费用的10%以上。定期的访问监控已被证明可以显著减少访问失败，并且在这里提出的设备可以进行频繁的低成本监控的情况下，失败率甚至会更低。这将带来广泛的好处，使患者获得更好的治疗效果，减少人员需求，并降低美国医疗保健行业飙升的成本。 公共卫生相关性：Sonetics的新型超声流量监测仪的成功开发对公共卫生的潜在益处包括：减少接受终末期肾病治疗的透析患者的健康并发症，由于流量监测设备对操作员的依赖性降低，减少了人员配置需求，以及由于透析患者对医疗保健系统的需求降低，降低了整个社会的医疗保健成本。此外，如果自动化血流传感得到更广泛的部署，健康结果将改善其他患者人群，如外周动脉疾病患者。